Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis

被引:53
作者
Kiebert, GM
Green, C
Murphy, C
Mitchell, JD
O'Brien, M
Burrell, A
Leigh, PN
机构
[1] MEDTAP Int, London, England
[2] Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Neurol, London WC2R 2LS, England
[3] Univ London Kings Coll, Inst Psychiat, London WC2R 2LS, England
[4] Royal Preston Hosp, Dept Neurol, Preston, Lancs, England
[5] Aventis Pharma, W Malling, Kent, England
关键词
health-related quality of life; utilities; amyotrophic lateral sclerosis;
D O I
10.1016/S0022-510X(01)00616-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: Amyotrophic lateral sclerosis (ALS) is a devastating disease that has serious consequences in terms of impairments and disabilities, which are expected to impact on health-related quality of life (HRQL). The aim of the present study was to assess self-reported health status and HRQL, as well as patients' own valuation of their present health state in a sample of patients with different levels of severity of ALS. Methods: Structured interviews were conducted with 77 patients with different levels of disease severity. Patients completed a disease-specific health status measure (ALSAQ-40), a generic health status measure (EuroQol EQ-5D), visual analogue scale (VAS) rating of current health and a standard gamble (SG) exercise to provide health state utilities for their own health state. Results: The results from the ALSAQ-40 and EQ-5D descriptive system indicate that patients' HRQL decreases systematically with increasing severity of disease. Patients' mean VAS rating of their own health ranged from 0.74 for stage 1 (early) disease severity, to 0.37 for stage 4 (late stage) disease severity. Utilities elicited via SG were systematically higher than VAS scores and ranged from a mean of 0.79 for stage 1 disease severity to a mean of 0.45 for stage 4 disease severity. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 29 条
[1]  
BENZIMON JT, 1994, NEW ENGL J MED, V330, P585
[2]  
BERNAT JL, 1987, NEUROLOGY
[3]   Palliative care in amyotrophic lateral sclerosis [J].
Borasio, GD ;
Voltz, R .
JOURNAL OF NEUROLOGY, 1997, 244 (Suppl 4) :S11-S17
[4]   TESTING THE VALIDITY OF THE EUROQOL AND COMPARING IT WITH THE SF-36 HEALTH SURVEY QUESTIONNAIRE [J].
BRAZIER, J ;
JONES, N ;
KIND, P .
QUALITY OF LIFE RESEARCH, 1993, 2 (03) :169-180
[5]  
BRAZIER JE, 1999, NHS HLTH TECHNOL ASS, V3, P1
[6]  
CAROSCIO JT, 1987, NEUROL CLIN, V29, P1
[7]  
CHURCHILL DN, 1991, CONTROL CLIN TRIALS, V12, P159
[8]   Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies [J].
Damiano, AM ;
Patrick, DL ;
Guzman, GI ;
Gawel, MJ ;
Gelinas, DF ;
Natter, HM ;
Ingalls, KK .
MEDICAL CARE, 1999, 37 (01) :15-26
[9]   Valuing health states: A comparison of methods [J].
Dolan, P ;
Gudex, C ;
Kind, P ;
Williams, A .
JOURNAL OF HEALTH ECONOMICS, 1996, 15 (02) :209-231
[10]   METHODOLOGY FOR MEASURING HEALTH-STATE PREFERENCES .2. SCALING METHODS [J].
FROBERG, DG ;
KANE, RL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1989, 42 (05) :459-471